sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
anesthetics
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p26
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
ethionamide
|
hydralazine
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p67
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
cinchophen
|
dextran
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p583
|
Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
|
sulfasalazine
|
ENBREL
|
EFFECT
|
Etanercept_ddi.xml
|
DDI-DrugBank.d341.s4
|
DDI-DrugBank.d341.s4.p0
|
Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
|
Lithium
|
lithium
|
NONE
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s5
|
DDI-DrugBank.d231.s5.p2
|
Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
|
ibuprofen
|
lithium
|
ADVISE
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s15
|
DDI-DrugBank.d415.s15.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
amitriptyline
|
itraconazole
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p149
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
adrenocortical steroids
|
warfarin sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p44
|
It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.
|
ketoprofen
|
lithium
|
ADVISE
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s25
|
DDI-DrugBank.d499.s25.p2
|
Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
|
probenecid
|
zalcitabine
|
MECHANISM
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s20
|
DDI-DrugBank.d263.s20.p10
|
Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
|
Ephedrine
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s16
|
DDI-DrugBank.d314.s16.p3
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
zidovudine
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p28
|
However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
|
UROXATRAL
|
alpha-blockers
|
ADVISE
|
Alfuzosin_ddi.xml
|
DDI-DrugBank.d273.s1
|
DDI-DrugBank.d273.s1.p0
|
Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
|
Sympathomimetic amines
|
veratrum alkaloids
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s2
|
DDI-DrugBank.d389.s2.p1
|
Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
|
nelfinavir
|
azithromycin
|
EFFECT
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s1
|
DDI-DrugBank.d53.s1.p0
|
The intake of furosemide and sucralfate should be separated by at least two hours.
|
furosemide
|
sucralfate
|
ADVISE
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s12
|
DDI-DrugBank.d231.s12.p0
|
Cimetidine has been shown to increase the bioavailability of labetalol HCl.
|
Cimetidine
|
labetalol HCl
|
MECHANISM
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s4
|
DDI-DrugBank.d412.s4.p0
|
However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
|
aspirin
|
NSAIDs
|
NONE
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s13
|
DDI-DrugBank.d440.s13.p12
|
FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
|
FLUOTHANE
|
tubocurarine
|
EFFECT
|
Halothane_ddi.xml
|
DDI-DrugBank.d74.s1
|
DDI-DrugBank.d74.s1.p0
|
Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
|
ketoconazole
|
ciclesonide
|
ADVISE
|
Ciclesonide_ddi.xml
|
DDI-DrugBank.d362.s5
|
DDI-DrugBank.d362.s5.p0
|
Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
|
indinavir
|
VIDEX
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s14
|
DDI-DrugBank.d43.s14.p5
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
flecainide
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p9
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
benzodiazepines
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p18
|
Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
|
acetaminophen
|
Gleevec
|
MECHANISM
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s16
|
DDI-DrugBank.d115.s16.p0
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
Flupenthixol
|
Ethanol
|
EFFECT
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p56
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
LEVSIN
|
monoamine oxidase (MAO) inhibitors
|
EFFECT
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p4
|
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
|
quinidine
|
calcium channel blocking agents
|
NONE
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s0
|
DDI-DrugBank.d226.s0.p10
|
Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
|
interleukin-1 antagonist
|
TNF-blocking agent
|
EFFECT
|
Adalimumab_ddi.xml
|
DDI-DrugBank.d493.s2
|
DDI-DrugBank.d493.s2.p5
|
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
|
ciprofloxacin
|
opiate
|
MECHANISM
|
11210403.xml
|
DDI-MedLine.d124.s1
|
DDI-MedLine.d124.s1.p3
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
sumatriptan
|
escitalopram
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p6
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
amitriptyline
|
lorazepam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p152
|
Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
|
Enoxacin
|
theophylline
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s21
|
DDI-DrugBank.d395.s21.p0
|
Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.
|
valdecoxib
|
omeprazole
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s42
|
DDI-DrugBank.d328.s42.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
alcohol
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p22
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
b-adrenergic blocking agents
|
phenobarbital
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p253
|
In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
|
oxcarbazepine
|
MHD
|
NONE
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s1
|
DDI-DrugBank.d307.s1.p2
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
lovastatin
|
hydrochlorothiazide
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p5
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
tricyclic antidepressants
|
antidepressants
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p0
|
Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
|
nicotine
|
Clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s15
|
DDI-DrugBank.d480.s15.p5
|
Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
|
efavirenz
|
contraceptives
|
ADVISE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s52
|
DDI-DrugBank.d531.s52.p0
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
chloramphenicol
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p4
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
paroxetine
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p4
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
estrogens
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p7
|
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.
|
Phenytoin
|
phenytoin
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s7
|
DDI-DrugBank.d438.s7.p1
|
Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.
|
Contraceptives
|
tiagabine
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s24
|
DDI-DrugBank.d277.s24.p0
|
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
|
VIRACEPT
|
Antimycobacterial agents
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s7
|
DDI-DrugBank.d340.s7.p0
|
When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
|
rifampicin
|
ofloxacin
|
EFFECT
|
11137650.xml
|
DDI-MedLine.d8.s6
|
DDI-MedLine.d8.s6.p8
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
ibuprofen
|
Oruvail
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p53
|
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
|
NSAIDs
|
aspirin
|
NONE
|
Ardeparin_ddi.xml
|
DDI-DrugBank.d105.s0
|
DDI-DrugBank.d105.s0.p12
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
colistin
|
lithium
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p86
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
nefazodone
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p15
|
Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
|
Antihistamines
|
alcohol
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s0
|
DDI-DrugBank.d389.s0.p2
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
chlorpromazine
|
Compazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p77
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
nicotinamide
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p17
|
Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
|
Beta-adrenergic receptor antagonists
|
BROVANA
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s12
|
DDI-DrugBank.d284.s12.p1
|
Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.
|
ketoconazole
|
VIRACEPT
|
MECHANISM
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s22
|
DDI-DrugBank.d340.s22.p3
|
An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
|
lithium
|
ATACAND
|
MECHANISM
|
Candesartan_ddi.xml
|
DDI-DrugBank.d547.s3
|
DDI-DrugBank.d547.s3.p3
|
In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
|
phenytoin
|
Mefloquine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s11
|
DDI-DrugBank.d220.s11.p18
|
Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
|
warfarin
|
NSAIDs
|
EFFECT
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s13
|
DDI-DrugBank.d400.s13.p2
|
Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
|
quinolones
|
didanosine
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s7
|
DDI-DrugBank.d562.s7.p4
|
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
|
levothyroxine sodium
|
sucralfate
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s2
|
DDI-DrugBank.d411.s2.p12
|
Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
|
moclobemide
|
almotriptan
|
MECHANISM
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s2
|
DDI-DrugBank.d299.s2.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Phenobarbital
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p7
|
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
|
d-amphetamine
|
protriptyline
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s8
|
DDI-DrugBank.d236.s8.p1
|
Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.
|
aluminum hydroxide
|
ketoprofen
|
NONE
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s3
|
DDI-DrugBank.d499.s3.p7
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
anticonvulsant drugs
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p10
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
warfarin
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p90
|
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
|
NUROMAX
|
phenytoin
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s6
|
DDI-DrugBank.d267.s6.p3
|
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
|
phenobarbital
|
carbamazepine
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s30
|
DDI-DrugBank.d124.s30.p2
|
Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
|
Grepafloxacin
|
caffeine
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s3
|
DDI-DrugBank.d78.s3.p10
|
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
|
benzodiazepines
|
diltiazem
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s8
|
DDI-DrugBank.d338.s8.p3
|
There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
|
etidronate
|
warfarin
|
EFFECT
|
Etidronic acid_ddi.xml
|
DDI-DrugBank.d327.s0
|
DDI-DrugBank.d327.s0.p0
|
The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
|
methylprednisolone
|
Aprepitant
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s14
|
DDI-DrugBank.d382.s14.p1
|
The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
|
cimetidine
|
diltiazem
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s14
|
DDI-DrugBank.d565.s14.p0
|
Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
|
colestipol hydrochloride
|
propranolol
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s5
|
DDI-DrugBank.d345.s5.p0
|
Amiodarone, disopyramide, lidocaine
|
Amiodarone
|
lidocaine
|
NONE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s63
|
DDI-DrugBank.d270.s63.p1
|
The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
|
griseofulvin
|
contraceptives
|
EFFECT
|
Griseofulvin_ddi.xml
|
DDI-DrugBank.d83.s2
|
DDI-DrugBank.d83.s2.p0
|
In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.
|
levothyroxine
|
estrogens
|
MECHANISM
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s12
|
DDI-DrugBank.d54.s12.p0
|
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
|
Warfarin
|
warfarin
|
NONE
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s16
|
DDI-DrugBank.d216.s16.p3
|
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
|
TIKOSYN
|
cimetidine
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s5
|
DDI-DrugBank.d558.s5.p6
|
Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
|
aspirin
|
iron
|
NONE
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s2
|
DDI-DrugBank.d75.s2.p9
|
Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.
|
L-phenylalanine
|
non-selective MAO inhibitors
|
EFFECT
|
L-Phenylalanine_ddi.xml
|
DDI-DrugBank.d530.s1
|
DDI-DrugBank.d530.s1.p0
|
Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
|
Aprepitant
|
norethindrone
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s19
|
DDI-DrugBank.d382.s19.p8
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
lovastatin
|
mitotane
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p473
|
Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
|
quinidine
|
aripiprazole
|
ADVISE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s16
|
DDI-DrugBank.d509.s16.p2
|
- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
|
sulphonylureas
|
Bezalip retard
|
EFFECT
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s3
|
DDI-DrugBank.d291.s3.p2
|
Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
|
zinc
|
Videx
|
NONE
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s7
|
DDI-DrugBank.d562.s7.p12
|
However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
|
quinolones
|
warfarin
|
EFFECT
|
Levofloxacin_ddi.xml
|
DDI-DrugBank.d242.s1
|
DDI-DrugBank.d242.s1.p3
|
Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.
|
fenoldopam
|
beta-blockers
|
ADVISE
|
Fenoldopam_ddi.xml
|
DDI-DrugBank.d546.s0
|
DDI-DrugBank.d546.s0.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
ibuprofen
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p21
|
Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
|
Norpace
|
quinidine
|
NONE
|
Disopyramide_ddi.xml
|
DDI-DrugBank.d506.s5
|
DDI-DrugBank.d506.s5.p2
|
Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
|
loracarbef
|
probenecid
|
MECHANISM
|
Loracarbef_ddi.xml
|
DDI-DrugBank.d351.s0
|
DDI-DrugBank.d351.s0.p7
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
dopamine
|
somatostatin analogs
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p347
|
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
|
pentobarbital
|
ouabain
|
EFFECT
|
1167743.xml
|
DDI-MedLine.d23.s1
|
DDI-MedLine.d23.s1.p21
|
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
|
antidiabetic products
|
ACE inhibitors
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s1
|
DDI-DrugBank.d313.s1.p0
|
Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
|
Corticosteroids
|
live attenuated vaccines
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s31
|
DDI-DrugBank.d314.s31.p0
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
Tegretol
|
Prozac
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p91
|
Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.
|
Furosemide
|
antihypertensive drugs
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s6
|
DDI-DrugBank.d231.s6.p0
|
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
|
oxacillin
|
diclofenac
|
NONE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s19
|
DDI-DrugBank.d249.s19.p20
|
Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
|
allopurinol
|
cypermethrin
|
EFFECT
|
11137320.xml
|
DDI-MedLine.d126.s6
|
DDI-MedLine.d126.s6.p1
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.